Physician profile
Mark Seigel
NPI 1366540080
$629.89
in general payments reported to CMS, 2019-2025
11 companies · $94.14 in 2025
The $94.14 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $33.62 · 2021: $25.62 · 2022: $19.10 · 2023: $11.75 · 2024: $24.38 · 2025: $94.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $130.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $152.47 | 2019 | |
| Abbvie INC. | $151.51 | 2019-2022 | |
| Smith+Nephew, INC. | $78.31 | 2019 | |
| Astellas Pharma US INC | $57.56 | 2024-2025 | Veozah |
| Hologic Sales and Service, LLC | $44.62 | 2020-2025 | Myosure Tissue Removal Device, Novasure |
| Amag Pharmaceuticals, INC. | $43.11 | 2019 | |
| Lilly USA, LLC | $37.77 | 2025 | Zepbound |
| Organon LLC | $25.39 | 2021-2023 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $24.17 | 2020-2021 | |
| Allergan, INC. | $14.98 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Seigel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.